In the present narrative review, we review the frequency of HR-related gene mutations in breast cancer and the data on PARPi efficacy in patients with ER+/HER2- breast cancers, especially HR+/HER2- breast cancers with high-risk features. This evidence concerns the gene ERBB2 and breast cancer.